绿脓杆菌制剂联合顺铂腔内治疗恶性胸水临床研究  

Clinical Study of PA-MSHA Vaccine in Adjuvant Treatment of Malignant Pleural Effusion

作　　者：路璐[1] 薛凡[2] 谢忠艳[2] 马庆[2] 

机构地区：[1]哈尔滨医科大学附属第四医院,黑龙江哈尔滨150001 [2]黑龙江省医学会,黑龙江哈尔滨150001

出　　处：《黑龙江医学》2010年第10期751-752,共2页Heilongjiang Medical Journal

摘　　要：目的比较绿脓杆菌制剂辅助胸腔化疗与单纯胸腔化疗对恶性胸水的近期临床疗效。方法 65例恶性胸水患者随机分成胸腔免疫化疗组和胸腔化疗组。胸腔免疫化疗组给予顺铂+绿脓杆菌制剂腔内治疗,胸腔化疗组给予单药顺铂腔内治疗。采用彩色多普勒超声测定患者治疗前后胸水消退率,治疗结束后评价临床疗效。结果在临床疗效评价中,胸腔免疫化疗组有效率(CR+PR)为72.73%,胸腔化疗组为43.75%,两组具有显著性差异(P<0.05)。结论绿脓杆菌制剂与化疗药物合用可提高恶性胸水腔内治疗的疗效,且安全性好。Objective To observe the effects of the pseudomonas aeruginosa with mannose sensitive hemagglutination pili（PA-MSHA） vaccine in adjuvant treatment of Malignant Pleural Effusion.Methods 65 cases of Malignant Pleural Effusion were treated with intrathoracic injection of cisplatin alone and cisplatin plus PA-MSHA.The levels of hydrothorax were determined by color Doppler ultrasound before and after the treatment.Results The short term effective rate of intrathoracic injection of cisplatin plus PA-MSHA on Malignant Pleural Effusion was 72.73%,higher than those in the cisplatin group 43.75% respectively（P〈0.05）.Conclusion The therapy of intrathoracic injection of cisplatin plus PA-MSHA was a simple,safe and effective method of treatment for Malignant Pleural Effusion.

关 键 词：恶性胸水 药物疗法 绿脓杆菌制剂 

分 类 号：R561[医药卫生—呼吸系统]